Sponsor: Syneos Health
With more than 30 biotech IPOs in 2017 but M & A deal activity running at lower than average levels, the tension for CEOs is delivering a confident story of how to achieve profitable growth for investors while drug launches receive more scrutiny than ever. As large biopharmas prune their portfolios and consider repatriation options, the expectations run higher than ever for an uptick in M & A this year. A highly distinguished panel of deal-makers will explore the impact these market forces will have on pharmaceutical and biotech companies as they strive to make the next big deal.
Session attendees will hear updated findings from two unique, forward-looking measures of deal-making in the industry the Syneos Health Dealmakers' Intentions Study and the BIO One-on-One Partnering Forecast. Based on a survey of more than 150 industry executives and business development professionals, Dealmakers' Intentions provides insight into what will likely drive the industry's partnering and M&A efforts moving forward and the implications for deal-making over the next year or more. Now in its tenth year, analysis will include year-over-year trends, deal metrics and broader M&A data.
Session ID: 228181